Published 9 July 2009, doi:10.1136/bmj.b2433
Cite this as: BMJ 2009;339:b2433

Research

Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis

Rosanne A H M van den Oord, Socrates research student, Aziz Sheikh, professor of primary care research and development

1 Allergy and Respiratory Research Group, Centre for Population Health Sciences, University of Edinburgh, Edinburgh EH8 9DX

Correspondence to: A Sheikh Aziz.Sheikh{at}ed.ac.uk

Objective To investigate whether filaggrin gene defects, present in up to one in 10 western Europeans and North Americans, increase the risk of developing allergic sensitisation and allergic disorders.

Design Systematic review and meta-analysis.

Data sources Medline, Embase, ISI Science Citation Index, BIOSIS, ISI Web of Knowledge, UK National Research Register, clinical trials.gov, the Index to Theses and Digital dissertations, and grey literature using OpenSIGLE.

Study selection Genetic epidemiological studies (family, case-control) of the association between filaggrin gene defects and allergic sensitisation or allergic disorders.

Data extraction Atopic eczema or dermatitis, food allergy, asthma, allergic rhinitis, and anaphylaxis, along with relevant immunological variables relating to the risk of allergic sensitisation as assessed by either positive skin prick testing or increased levels of allergen specific IgE.

Data synthesis 24 studies were included. The odds of developing allergic sensitisation was 1.91 (95% confidence interval 1.44 to 2.54) in the family studies and 1.57 (1.20 to 2.07) in the case-control studies. The odds of developing atopic eczema was 1.99 (1.72 to 2.31) in the family studies and 4.78 (3.31 to 6.92) in the case-control studies. Three studies investigated the association between filaggrin gene mutations and allergic rhinitis in people without atopic eczema: overall odds ratio 1.78 (1.16 to 2.73). The four studies that investigated the association between filaggrin gene mutations and allergic rhinitis in people with atopic eczema reported a significant association: pooled odds ratio from case-control studies 2.84 (2.08 to 3.88). An overall odds ratio for the association between filaggrin gene mutations and asthma in people with atopic eczema was 2.79 (1.77 to 4.41) in case-control studies and 2.30 (1.66 to 3.18) in family studies. None of the studies that investigated filaggrin gene mutations and asthma in people without atopic eczema reported a significant association; overall odds ratio was 1.30 (0.7 to 2.30) in the case-control studies. The funnel plots suggested that publication bias was unlikely to be an explanation for these findings. No studies investigated the association between filaggrin gene mutations and food allergy or anaphylaxis.

Conclusions Filaggrin gene defects increase the risk of developing allergic sensitisation, atopic eczema, and allergic rhinitis. Evidence of the relation between filaggrin gene mutations and atopic eczema was strong, with people manifesting increased severity and persistence of disease. Filaggrin gene mutations also increased the risk of asthma in people with atopic eczema. Restoring skin barrier function in filaggrin deficient people in early life may help prevent the development of sensitisation and halt the development and progression of allergic disease.

© Oord et al 2009
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Articles

Gene defects and allergy
Hugo Van Bever, Birgit Lane, and John Common
BMJ 2009 339: b1203. [Extract] [Full Text]

The case of the misleading funnel plot
Joseph Lau, John P A Ioannidis, Norma Terrin, Christopher H Schmid, and Ingram Olkin
BMJ 2006 333: 597-600. [Full Text] [PDF]

This article has been cited by other articles:

  • Treadwell, P. (2009). Information on genetic defect may enhance eczema treatments. AAP News 30: 12-12 [Full text]  
  • (2009). Filaggrin-Atopy Update. Journal Watch Dermatology 2009: 4-4 [Full text]  
  • Bever, H. V., Lane, B., Common, J. (2009). Gene defects and allergy. BMJ 339: b1203-b1203 [Full text]  

Rapid Responses:

Read all Rapid Responses

No association with psoriasis
Alan D Irvine
bmj.com, 12 Jul 2009 [Full text]



Access jobs at BMJ Careers
Whats new online at Student 

BMJ